[Letter to Daniel Zagury from Ann H. Sliski]

ur. 1Lagury

Aireement for Receiving H9 or H9/HTLV-IIIg Cell Line
I have read and agree to adhere to the following guidelines
for use of H9/HTLV-IIIB:
1. Use of H9 or H9/HTLV-IIIB will be limited
to my immediate laboratory. I will not give
it out without prior written approval from
Dr. Gallo.
2. Work performed will be on a collaborative
basis with Dr. Gallo and his laboratory
unless stated otherwise.
3. H9 or H9/HTLV-III will not be used for
commercial purposes. A U.S. Government
(National Cancer Institute) patent is in
effect.
4. Use of the H9/HTLV-IIIB line or virus
produced from it will be according to U.S.
Government recommendations (see attached).
Work can be carried out in a biosafety level 2
facility if the equipment, techniques and
access to the work area are maintained as
biosafety level 3. Large scale production of
the virus requires strict biosafety level 3
containment.
5. Any operations using the infected cell
outside of biocontainment will be after
treatment such as gluteraldehyde fixation.
Signature_ _ _ ___ Date
(Please type or print name and address below)
Dr. Daniel Zagury
Physiologie Cellulaire
Universite Pierre et Marie Curie
U.E.R. 61
4, Place Jussieu
75005 Paris
France